
|Videos|June 1, 2017
Comparing Neoadjuvant Chemotherapy Versus Surgery in Ovarian Cancer Care
Author(s)Emma Barber, MD
Emma Barber, MD, UNC Department of Obstetrics and Gynecology, UNC School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses which patients with ovarian cancer are better candidates for neoadjuvant chemotherapy versus surgery.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Long-Term OMNIVORE Data Show Durable Treatment-Free Survival in RCC
2
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
3
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
4
Phase 3 ENHANCE Trial: Magrolimab Adds Toxicity, Not Benefit, in MDS
5































